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 Mammalian cells are extensively used for the production of protein therapeutics due to 
their increased biocompatibility—when compared to those produced by bacteria, yeast, and plant 
eukaryotes—which stems from their ability to perform post-translational modifications. 
However, one of the main drawbacks of using mammalian expression systems is that they have 
an absolute dependence nine essential amino acids: histidine, isoleucine, leucine, lysine, 
methionine, phenylalanine, threonine, tryptophan, and valine. Furthermore, there are higher 
energy demands necessary for increased protein production. Increased citric acid cycle activity 
has been shown to decrease toxic byproduct accumulation from mammalian cell cultures while 
supplying an increased amount of ATP that is crucial to the higher energy demands necessary.  
 In order to address these challenges within mammalian cell culture, this work aimed at 
reconstructing the threonine, isoleucine, and valine biosynthetic pathways in human cell lines. A 
U-2 OS human osteosarcoma cell line capable of producing its own threonine was provided by 
the Silver Lab. Viability studies with a negative control cell line provided further evidence that 
this cell line was in fact expressing the threonine biosynthetic pathway. Furthermore, the genes 
that create the isoleucine and valine biosynthesis pathway were successfully expressed in HEK 
cells, a more industrially relevant cell line. Finally, the production of oxobutanoate, the first 
metabolite in the isoleucine and valine pathway, was proved through GC-MS analysis. In 
pursuance of increased citric acid cycle activity, PGC-1α was overexpressed transiently in HEK 
cells as verified through Western blot. Finally, a mitochondrial content assay was performed in 
an attempt to prove more mitochondrial biogenesis as a result of PGC-1α overexpression. 
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Chapter 1: Introduction 
1.1 Essential Amino Acids  
The biotechnology industry continues to rapidly expand each year due to the increasing 
production and use of biopharmaceuticals. In fact, biopharmaceuticals represent half of all drugs 
in development and 20% of all new drug approvals [1]. In 2014, the total revenue of 
biotechnology within the four established clusters (companies located within the United States, 
Europe, Australia, and Canada) was $123B—with $93B alone coming from the United States—a 
growth of over 23% from 2013 [2].  
 Simple organisms such as bacteria and yeast have been traditionally used for production 
of numerous pharmaceutical and proteins such as insulin [3]. However, it has become 
progressively preferred to produce recombinant proteins for biotherapeutic use in humans from 
mammalian cells such as Chinese Hamster Ovary (CHO) and Human Embryonic Kidney 
(HEK293) [4]. Mammalian cells are often favored as expression systems due to their increased 
biocompatibility, which stems from their ability to perform post-translational modifications. 
Some post translational modifications such as glycosylation and folding are essential for 
stability, efficacy, and avoidance of unwanted immune responses of recombinant proteins that 
will be used for therapeutic or research purposes [5, 6, 7]. However, these more advanced 
functions require compartmentalization—a key distinguishing feature between higher order 
eukaryotes and other organisms [8].  
 A significant difference between mammals (including humans) and many bacteria, yeast, 
and plant eukaryotes is absolute dependence on nine essential amino acids for growth and 
survival. These essential amino acids include: histidine, isoleucine, leucine, lysine, methionine, 
phenylalanine, threonine, tryptophan and valine (Figure 1) [9, 10]. It is especially notable that 
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leucine, threonine, and valine—essential amino acids—are amongst the more abounding in the 
human body as evidenced by their representation of 24.4% of the amino acid content humans 
[11]. In addition, some amino acids require more ATP for production than others. For example, 
threonine and valine require an expenditure of 18.7 and 23.3 ATP respectively, while non-
essential arginine expends 27.3 ATP—the same cost for leucine synthesis [12]. This supports the 
notion that there may be reasons other than energy costs as to why the essential amino acid 
biosynthetic pathways were eliminated.  
 It is feasible that the essential amino acid synthesis pathways can lead to the production 
of undesirable side-products, feedback products, or other unwelcome regulatory mechanisms. 
For example, the enzymes in the branched chain amino acid pathways—isoleucine, leucine, and 
valine—show “low substrate specificity” [13]. This warrants enzymatic multifunctionality as 
evidenced through synthesis of isoleucine and valine from the same enzymes. Yet, this is not 
necessarily beneficial in the case of isoleucine and valine because the biosynthetic enzymes 
involved can accept non-specific substrates in addition to the alpha-keto acids produced in the 
isoleucine pathways. This can lead to the production of modified amino acids such as norvaline 
and norleucine, in addition to the conventional amino acids. Complications can arise due to mis-
aminoacylyation of these alternate amino acids into the tRNA of leucine and methionine, along 
with their integration into proteins [14]. The engineering of select essential amino acid pathways 










































Threonine is an essential polar amino acid with an alcohol group and is encoded by the 
codons ACU, ACA, ACC, and ACG. It is produced by the emergence of aspartate from the TCA 
in microbes and plants—it is ingested in humans (Figure 2). Feedback inhibition occurs in this 
biosynthetic pathway where threonine inhibits aspartate kinase, homoserine dehydrogenase, and 
homoserine kinase [15]. Lysine can also inhibit aspartate kinase I which introduces a prospective 
bottleneck in the production of all metabolites in the aspartate family. Threonine is degraded via 
threonine dehydrogenase into glycine by 2-amino-3-ketobutyrate and into ammonia and 2-
oxobutanoic acid by serine/threonine dehydratase [16]. Finally, the absence of a functional 
threonine dehydrogenase gene in humans suggests that the dehydratase maintains the 











 Valine is an essential nonpolar branched chain amino acid encoded by codons GUU, 
GUC, GUA and GUG. Valine is synthesized in microbes and plants through the multistep 
pathway shown in Figure 3 [19]. Valine is synthesized from 2-oxoisovalerate—or alpha-
ketoisovalerate—by amino acid transaminase enzyme (ILVE). The same enzymes are involved 
in the synthesis of isoleucine. The leucine biosynthesis pathway also uses the same pathway but 
branches off after 2-oxovalerate. Similar to the threonine biosynthesis pathway, the first step in 
this pathway which is catalyzed by acetolactate synthesis undergoes feedback inhibition by both 
valine and leucine [20]. Valine and the other branched chain amino acids—isoleucine, and 
leucine—are degraded through the branched chain alpha-keto acid dehydrogenase complex. A 
deficiency in this complex leads to maple syrup urine disease [21]. The complex degrades the 
branched chain amino acids into Acyl-Co derivatives and eventually acetyl-Co or succinyl-CoA 
for entry in TCA cycle. 
1.1.3. Isoleucine 
Isoleucine is a hydrophobic amino acid encoded by the three codons AUU, AUC, and 
AUA. Threonine is converted to 2-oxobutanoate (or alpha-ketobutyrate) with an ammonia 
byproduct via threonine dehydratase as the initial step of isoleucine biosynthesis (Figure 3). The 
remaining enzymes in the pathway are collective with valine synthesis. The final step—which 
involves the conversion of 3-methyl-2-oxopentanoate (or 2-oxo-3-methylvalerate/keto-
methylvalerate)—is catalyzed by amino acid transaminase enzyme (ILVE). Threonine 
dehydratase, the first enzyme in the pathway, is also subject to feedback inhibition by isoleucine 
and feedback activation by valine [22].  
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There is an alternative isoleucine pathway that can completely bypass the threonine 
pathway and the utilization of threonine dehydratase—along with avoiding the challenge of 
feedback inhibition. Isoleucine biosynthesis in G. sulfurreducens [23] and cyanobacterial species 
[24] uses acetyl-CoA and pyruvate to produce 2-oxobutanoate (alpha-ketobutyrate) through 
citramalate. In this pathway, citramalate is generated from acety-CoA and pyruvate by the CimA 
enzyme. (Figure 4). This is then followed by conversion to citraconate, then beta-methyl-D-
malate, and finally 2-oxobutanoate—the first dedicated substrate in the isoleucine pathway. This 
pathway can proceed using the leucine pathway enzymes and serves to generate NADH in 
addition to 2-oxobutanoate [25]. Thus, the 2-oxobutanoate precursor can be synthesized from 





Figure 3: Isoleucine and Valine Biosynthetic Pathway 













 Leucine is another essential branched chain amino acid with an isobutyl side chain 
resulting in its hydrophobicity. Is it coded for by the following six codons: UUA, UUG, UUC, 
CUC, CUA, and CUG. Leucine is synthesized from pyruvic acid in multiple steps—with the first 
ones being shared with the valine synthesis pathway. At the metabolic intermediate 2-
oxovalerate (alpha-ketoisovalerate), the leucine pathway diverges with the production of 2-
isopropylmalate by isopropylmalate synthase otherwise known as LeuA (Figure 5). After a series 
of steps, leucine is synthesized by the amino acid transferase (ILVE) that is common to the 
isoleucine and valine pathways as well. Leucine regulates the pathway through feedback 
inhibition of the first step catalyzed by LeuA. Additionally, leucine regulates the first step in the 












 Peroxisome proliferator-activated receptor (PPAR)-γ coactivator (PGC)-1α is a 
transcriptional coactivator that regulates genes involved in energy metabolism through 
stimulation of mitochondrial biogenesis and function along with other key metabolic functions 
[27]. PGC-1α acts as a coactivator for a number of transcription factors involved in 
mitochondrial biogenesis such as nuclear respiratory factor (NFR) 1 and 2, along with estrogen-
related receptor (EFR) α, β, and γ [28, 29, 30]. Additionally, PGC-1α is a coactivator for a 
number of other transcription factors that are involved in fatty acid oxidation, gluconeogenesis, 
and triglyceride metabolism [31, 32, 33, 34, 35, 36].  PGC-1α was first identified as a 
transcription coactivator of adaptive thermogenesis induced by a cold environment. Adaptive 
thermogenesis is the process of heat dissipation in response to environmental changes in 
temperature and diet [37, 38].  
PGC-1α also plays a role in skeletal muscle fiber conversion. PGC-1α expression is 
induced by short and long term exercise in humans and rodents. This results in an increase in the 
ratio of glycolytic fibers to oxidative fibers [39, 40, 41, 42]. PGC-1α similarly participates in 
heart development. An increase in expression level is followed by a considerable surge in 
mitochondria biogenesis and oxidative metabolism in a developing heart [43]. In addition, PGC-
1α overexpression can initiate the expression of gluconeogenic genes in primary hepatocytes 
[44]. This has been further validated through studies in PGC-1α knockout mice which showed 
fasting hypoglycemia during conditions of compromised gluconeogenic gene expression [45, 
35]. Furthermore, PGC-1α plays a role in Type 2 diabetes through downregulation in muscle 
tissues [29, 46, 47]. In addition, a polymorphism of the PGC-1α gene that results in reduced 
activity has been associated with an increased risk for type 2 diabetes [48, 49]. It is therefore 
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believed that reduced PCG-1α activity can lead to insulin resistance. Finally, the use of PCG-1α 
overexpression for upregulation of mitochondrial oxidative metabolism will be furthered 



























Chapter 2: Engineering of Essential Amino Acid Pathways into U-2 OS Cells 
 
2.1 Introduction 
As previously mentioned, mammalian cells lack the capabilities to synthesize essential 
amino acids. If these amino acid requirements could be removed from mammalian cell culture, 
then the production of biotherapeutics could lower the costs associated with their culture media. 
The simplification of mammalian cell culture formulations could lower the costs of mammalian 
biomanufacturing and in thus lead to reduced biopharmaceutical costs. 
2.1.1 Threonine Biosynthetic Pathway 
  The threonine biosynthetic pathway consists of five steps beginning with aspartic acid. 
The first reaction involves the conversion of aspartic acid into aspartyl phosphate through the 
transfer of a phosphate group from ATP by aspartate kinase 1. The Escherichia coli gene for 
aspartate kinase 1 is thrA.  The second step uses aspartic semialdehylde dehydrogenase—its 
respective E. coli gene is known as asd—to convert the aspartyl phosphate into aspartic β-
semialdehyde. It utilizes an NADPH and a hydrogen ion and releases NADP+ and a phosphate 
group as a byproduct. The third step consists of the conversion of aspartic β-semialdehyde into 
homoserine through homoserine dehydrogenase (metL). It utilizes an NDAPH and a hydrogen 
ion and releases an NADP+ as a byproduct. The fourth step converts homoserine into 
homoserine o-phosphate through the transfer of a phosphate group from ATP by homoserine 
kinase (thrB). The final step uses threonine synthase (thrC) to convert homoserine o-phosphate 





2.1.2 Isoleucine and Leucine Biosynthetic Pathway 
 The isoleucine and leucine biosynthetic pathways share the same enzymes. The first step 
in the production of isoleucine begins with the conversion of threonine to 2-oxobutanoate (or 
alpha-ketobutyrate) through threonine dehydratase (ILVA/ILV1) with ammonia as the 
byproduct. The subsequent step converts 2-oxobutanoate with pyruvate to (S)-2-aceto-2-
hydroxybutanoate with CO2 as a byproduct via acetolactate synthase (ILVBN/ILV2-6). The third 
step is the conversion to (R)-3-hydroxy-3-methyl-2-oxopentanoate with NADPH and a hydrogen 
ion via ketol-acid reductoisomerase (ILVC/ILV3) with NADP+ as a byproduct.  The fourth step 
also uses ketol-acid reductoisomerase (ILVC/ILV3) to create (R)-2,3-Dihidroxy-3-
methylpentanoate. The fifth step converts (R)-2,3-Dihydroxy-3-methylpentanoate into (S)-3-
Methyl-2-oxopentanoate via dihydroxy acid dehydratase (ILVD/ILV5) with water as a 
byproduct. The final step towards isoleucine biosynthesis is the conversion of (S)-3-Methyl-2-
oxopentanoate utilizing glutamate via amino-acid transaminase (ILVE) with alpha ketoglutarate 
as the byproduct [50].  
 The first step in valine biosynthesis is the conversion of pyruvate in 2-hydroxyethyl-
ThPP with ThPP as a cofactor via acetolactate synthase (ILVBN/ILV2-ILV6). The second step 
also involves the use of acetolactate synthase (ILVBN/ILV2-ILV6) with pyruvate as a cofactor 
to convert 2-hydroxyethyl-ThPP into (S)-2-acetolactate with CO2 as a byproduct. The following 
step converts (s)-2-acetolactate into 3-hydroxy-3-methyl-2-oxobutanoate with a hydrogen ion 
and NADPH via ketol-acid reductoisomerase (ILVC/ILV3) producing NADP+ as a byproduct. 
The fourth step also utilizes ketol-acid reductoisomerase (ILVC/ILV3) to create (R)-2,3, 
dihydroxy-3-methylbutanoate. The fifth step converts that into oxoisovalerate with water as a 
byproduct through dihydroxy dehydratase (ILVD/ILV5). The final step uses glutamate and 
16 
 
pyruvate via amino-acid transaminase (ILVE) with 2-oxoglutarae and alanine as byproducts to 
produce valine [50].   
2.2 Materials and Methods 
2.2.1 Cell Culture and Cell Lines 
 Aseptic cell culture was performed in a biosafety cabinet (Labconco, Kansas City, MO). 
Cells were incubated at 37° C and 5% CO2 in humidified incubators (Thermo Fisher Scientific, 
Carlsbad, CA). U-2 OS and U-2 OS threonine prototroph adherent cell lines were kindly 
provided by Wade Hicks from Dr. Pamela Silver’s lab at Harvard University. U-2 OS cells are a 
human osteosarcoma cell line. To create the threonine prototroph, the U-2 OS cells were 
transformed in a one-step transfection with the plasmid shown in Figure 6 and selected through 
threonine-deprived Dulbecco’s modified Eagle’s medium (DMEM) media (Thermo Fisher 
Scientific, Carlsbad, CA). Cells were supplemented with 10% dialyzed Fetal Bovine Serum 
(Thermo Fisher Scientific, Carlsbad, CA) and 2.5 mM aspartic acid (Sigma Aldrich). 
Untransfected U-2 OS cells were used as a control cell line for various experiments.  
2.2.2 Viability Studies 
 U-2 OS cells and U-2 OS threonine prototrophic cells were plated at 450,000 cells/well in 
six well tissue culture treated plates (Corning, Corning, NY). They were each placed under three 
conditions: 4.5 g/L Dulbecco’s modified Eagle’s medium (DMEM) media supplemented with 
10% Fetal Bovine Serum, threonine-deprived Dulbecco’s modified Eagle’s medium (DMEM) 
media supplemented with dialyzed Fetal Bovine Serum, and threonine-deprived DMEM media 
supplemented with dialyzed Fetal Bovine Serum and 2.5 mM aspartic acid (Sigma Aldrich). Cell 
counts were taken every 24 hours for six days. One well from each condition was harvested 
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using the media from each well to detach the cells from the well of interest. Triplicate live/dead 
cell counts from each of well were performed every day using trypan blue solution (Corning, 
Corning, NY). Cells were counted on a light microscope (Zeiss, Oberkochen, Germany) using a 
hemocytometer (Electron Microscopy Sciences, Hatfield, PA).  
2.2.3 DNA Constructs and Transfection 
2.2.3.1 Bacterial Genes 
 The genes needed to complete the threonine pathway—thrA, thrB, thrC, and asd—and 
the isoleucine-valine pathway—ILVA, ILVB, ILVC, ILVD, and ILVN—were amplified from E. 
coli by performing polymerase chain reaction (PCR) and inserted into the pFUSE-like vector 
using Gibson assembly. All genes were separated by the porcine teschovirus 2A peptide 
sequence inserted between genes to allow the use of a single CMV promoter and a polycistronic 




Figure 6: Polycistronic transcripts containing genes for threonine, isoleucine, and valine. (A) Vector 
containing genes for bacterial threonine biosynthetic pathway. (B) Vector containing genes for bacterial 
isoleucine and valine biosynthetic pathway. 
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2.2.3.2 Yeast Genes  
 The genes needed to complete the isoleucine valine-pathway—ILV1, ILV2, ILV3, ILV5, 
and ILV6—were amplified from S. cerevisiae by performing polymerase chain reaction (PCR) 
and individually inserted into the pBudCE4.1 plasmid shown in Figure 7 (Thermo Fisher 
Scientific, Carlsbad, CA). The individual genes are all under the EF-1α promoter using the 




 Lipofectamine 3000 reagent (Thermo Fisher Scientific, Carlsbad, CA) was used to 
transfect the vectors into both U-2 OS and U-2OS threonine prototrophic cell lines in Opti-MEM 
I media (Thermo Fisher Scientific, Carlsbad, CA) according to the manufacturers protocol.   
 
Figure 7: pBudCE4.1 plasmid from Thermo Fisher Scientific 
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2.2.4 13C Aspartic Acid  
 Universally labeled 13C aspartic acid was purchased from Sigma-Aldrich. A 30mM stock 
solution of the aspartic acid tracers were prepared by dissolving 100 mg of the 13C aspartic acid 
into 25 mL of water and heating to 37°C for four hours. The solution was then filter sterilized 
with a 0.2 μm filter. A concentration of 1 mM aspartic acid was used in the culture medium for 
labeling experiments.   
2.2.5 GC-MS Analysis 
 Intracellular metabolites were extracted from six well tissue culture treated plates and ten 
centimeter culture treated plates (Corning, Corning, NY) by washing twice with 4°C cold saline 
at 9g/L NaCl. Then cell metabolism was quenched with cold methanol and the plates were 
incubated on ice for five minutes. Afterwards, the cells were scraped off of the plate surfaces. 
Next the suspension was transferred into glass tubes with teflon-sealed caps. The next step 
involved the addition of 1.5 mL of chloroform and vigorously vortexing for ten seconds. 
Subsequently, 1.5 mL of water was added to suspend cell debris which was then followed by 
vigorous vortexing for one minute. Afterwards, the samples were stored overnight at 4°C. The 
next day, samples were centrifuged at 2000 rpm and 4°C for 20 minutes. The upper phase with 
methanol and water was then transferred to two 1.5 mL Eppendorf tubes and evaporated to 
dryness under nitrogen gas at 37°C.  
 Derivitization and GC-MS analysis was graciously performed at the Antoniewicz lab. 
After drying, the metabolites were suspended in 50 μL of 2% wt methoxylamine hydrochloride 
in pyridine and incubated at 37°C for 90 minutes on a heating block. After 70 μL of MTBSTFA 
+ 1% TBDMS was added to the samples, they were incubated at 60°C for 30 minutes. The next 
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step involved incubating the samples at room temperature overnight. Then, the derivatized 
samples were centrifuged for two minutes at 14,000g. Then supernatants were then transferred to 
GC vials for the GC-MS analysis. Sample volumes of 1 μL were injected in split mode with split 
ration ranging from 1:2 to 1:5. Over the 75-minute run time, the GC oven temperature was varied 
as follows: temperature was held at 70°C for two minutes, then increased to 140°C at a rate of 
3°C per minute, then increased to 150°C at 1°C per minute, then increased to 242°C at 3°C per 
minute, and finally increased to 280°C at 10° per minute. This temperature was maintained 
constant until the end of the 75-minute run time. The mass spectra of selected metabolite 
fragments were collected in SIR mode.  
The GC-MS analysis was performed using an Agilent 7890A GC equipped with a DB-
5ms capillary column (30 m x 0.25 mm i.d. x 0.25 μm; Agilent J&W Scientific) for analysis of 
aqueous metabolites. The GC instrumented interfaces with a Waters Quatro Micro GC-MS/MS 
(Milford, MA) operating under electron impact ionization at 70 eV and 200°C ion source 
temperature. The injection port and interface temperatures were 250°C. Helium flow was 
maintained at 1mL/min. Mass spectra were recorded in selected ion recording (SIR) mode with 
30 ms dwell time [51]. 
2.3 Results 
2.3.1 Viability Studies 
 To determine the impact of essential amino acid depletion on U-2 OS cells, cells were 
cultured under three conditions: threonine limited media, threonine limited media supplemented 
with 2.5 mM aspartic acid, and normal DMEM media. The same culture practices were also 
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performed on a U-2 OS threonine prototrophic cell line in order to determine the viability effects 
as well as to verify the presence of the threonine biosynthetic pathway.  
 The U-2 OS cells had similar viabilities on the first day (Figure 8); however, on Day 2, 
there was a significant decrease in the viability of the cells cultured without threonine—
including those supplemented with aspartic acid—when compared to the cells cultured on 
normal DMEM media. While the viability improves slightly for the U-2 OS cells on days three 
and four, the viability is significantly less than the cells on normal media. Furthermore, on days 
five and six, the viability of the cells cultured on threonine limited media and threonine limited 
media with aspartic acid falls drastically. While the viability for the U-2 OS cells cultured on 
normal media also fall, the viability is much higher than those cells on limited media. In 
summary, U-2 OS viability is not sustainable on threonine depleted media. 
 The U-2 OS threonine prototrophic cells maintained similar viabilities across all three 
conditions (Figure 9). On Day 1, the viabilities of threonine limited media, threonine limited 
media supplemented with aspartic acid, and normal media are nearly indistinguishable. By day 
four, the viabilities begin to fall slightly. While the threonine prototrophic cells have a lower 
viability than the other conditions at Day 5, it is evident than the cells that have been 
supplemented with aspartic acid maintain higher viability by the last days of the study. 
 The most telling results are when the U-2 OS and U-2 OS threonine prototrophic cells are 
compared (Figure 10-11). On Day 1, the U-2 OS cells under all conditions are very similar to the 
threonine prototroph cell line. However, by Day 2, the viability of the U-2 OS cells under 
threonine limited media are much lower than those under the other conditions. U-2 OS cells in 
normal media maintain a high viability—with a slight decrease that begins on Day 5—along with 









Figure 8: U-2 OS viability under threonine limited media, threonine limited 
media supplemented with 2.5 mM aspartic acid, and normal media. 
Figure 9: U-2 OS threonine prototroph viability under threonine limited 
media, threonine limited media supplemented with 2.5 mM aspartic acid, 





























U-2 OS vs U-2 OS Thr Viability: Limited Media
U-2 OS Limited
U-2 OS Normal
U-2 OS Thr Limited




















U-2 OS vs U-2 OS Thr Viability: Limited Media + 
2.5 mM Asp
U-2 OS Limited & 2.5 mM Asp
U-2 OS Thr Limited & 2.5 mM
Asp
Figure 10: U-2 OS vs U-2 OS threonine prototroph viability under 
threonine limited media, and normal media. 
Figure 11: U-2 OS vs U-2 OS threonine prototroph viability under 
threonine limited media supplemented with 2.5 mM aspartic acid. 
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 When looking at the cell counts, the raw numbers support the viability analysis. When 
comparing the cell densities of live cells under the tested conditions, it is evident that the U-2 OS 
cells cannot survive without threonine while the prototrophic cell line does. Figure 12 shows 
similar growth between both cells on the first day, but by the second day the U-2 OS cells greatly 
decrease in number while the prototrophic cells remain steady. While by day four the U-2 OS 
Thr cell line decreased in density, it was maintained higher than the U-2 OS cell line for the 
duration of the study. When supplementing the limited media with Aspartate, there was a more 
notable difference between the two cell lines. The threonine prototrophic cells maintained a 
much higher cell density throughout the experiment (Figure 13). Finally, when comparing the 
two cell lines under normal media conditions, they show a similar growth pattern, with the 






















Limited Media: U-2 OS vs U-2 OS Thr
U-2 OS Limited (Live)
U-2 OS Threonine Limited (Live)
Figure 12: U-2 OS vs U-2 OS threonine prototroph cell density under 























Limited Media + 2.5 mM Asp: 
U-2 OS vs U-2 OS Thr
U-2 OS Limited + Asp (Live)

















Normal Media: U-2 OS vs U-2 OS Thr
U-2 OS Normal (Live)
U-2 OS Threonine Normal (Live)
Figure 13: U-2 OS vs U-2 OS threonine prototroph cell density under 
threonine limited media supplemented with 2.5 mM aspartic acid. 




2.3.2 GC-MS and 13C Aspartic Acid Analysis  
 The results of these studies are pending. They will be presented in the future work as the 
data is still being analyzed.  
2.4 Discussion 
 The viability studies demonstrated that U-2 OS cells—a human cell line—cannot 
maintain desirable viability when they are cultured without threonine. This confirms that 
mammalian cells cannot maintain viable without essential amino acids—even if they are lacking 
only threonine as in this case. Perhaps the most important deduction that can be drawn from this 
viability study is that the U-2 OS cell line that was transfected with the threonine biosynthetic 
cell line and selected for using threonine limited media may in fact be producing its own 
threonine. The self-production of threonine is also supported by the fact that supplementation 
with aspartic acid maintains the highest viability by the end of the study. Aspartic acid feeds into 
the threonine biosynthetic pathway that was transfected and therefore requires aspartic acid to 
function. This study also supports the selection of method that was used to generate the threonine 
prototrophic cell line. In the continuation of engineering a human cell line capable of producing 
all of the essential amino acids, selection through essential amino acid derived media may be a 







Chapter 3: Engineering of Essential Amino Acid Pathways in HEK293t Cells 
 
3.1 Introduction 
 Monoclonal antibodies, peptides, and recombinant proteins are some of the most widely 
produced biomolecules manufactured by the pharmaceutical industry [52, 53]. These 
therapeutics can be produced using bacterial, yeast, plant, insect, and mammalian expression 
systems [54]. Expression systems are chosen depending on the proteins of interest. In the case of 
producing biopharmaceuticals, mammalian cell lines are preferred due to their ability to produce 
large, complex proteins such as membrane proteins and perform post translational 
modifications—most importantly glycosylation—that are compatible with humans [52, 54, 55]. 
The most common non-human mammalian cell line used for biotherapeutic production are 
Chinese hamster ovary (CHO) cells; however, this cell line can produce post translational 
modifications that are not expressed in humans [56]. This presents challenges because non-
human cell lines must be screened during production in order to identify clones with compatible 
glycan profiles [57]. 
 The challenges with non-human, mammalian expression systems have given rise to the 
increases interest in human cell lines such as human embryonic kidney (HEK293) for 
biotherapeutic production due to their ability to synthesize proteins that are more analogous to 
those in humans [57]. Human cells have an advanced protein glycosylation ability as evidenced 
by approximately 2% of the human transcriptome encoding for proteins involved in 
glycosylation [58]. When producing proteins to treat human disease, using proteins that originate 
from human cells can help decrease the probability of inducing undesired immune responses as 
compared to those originating from non-human sources. While HEK293 cells include the 
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oligosaccharide synthetic capabilities, they lack the minimalist cell capabilities of creating 
fundamental amino acid building blocks from basic nutrients that are present in bacteria, plants, 
and fungi—that is, the essential amino acids: histidine, isoleucine, leucine, lysine, methionine, 
phenylalanine, threonine, tryptophan, and valine [59]. 
 Due to human cells lacking amino acid minimalist capabilities, the biopharmaceutical 
industry has optimized cell culture media formulations to provide all of the necessary nutrients 
such as the essential amino acids, glucose, growth factors, and buffers. However, adding these 
nutrients is extremely costly. With the arguments previously stated, it is evident that it would be 
beneficial to re-create the biosynthetic pathways for the essential amino acids into a human cell 
line—in this case the widely used HEK293 cell line—in order to maximize their efficiency and 
productivity while reducing culture costs in an industrial setting. While there are still a number 
of disadvantages to using human cell lines such as the potential susceptibility to human viral 
contamination, and the fact that clinical experience is still not as widespread, there a number of 
benefits to using HEK293 cells. These cells can be easily grown in suspension, they divide 
quickly, they are responsible to a number of transfection methods, and are very efficient at 
protein production [60, 61]. 
 HEK293 cells have also recently been used to produce therapeutics approved by the 
Federal Drug Administration (FDA) and/or the European Medicines Agency (EMA). Some of 
these drugs include drotrecogin alfa for severe septic shock treatment (XIGRIS®; Eli Lilly 
Corporation, Indianapolis, IN), recombinant factor IX Fc fusion protein (rFIXIC; Biogen, 
Cambridge, MA) and human cell line recombinant factor VIII (human-cl rhFVIII; NUWIQ®; 
Octapharma, Lachen, Switzerland) used to treat hemophilia A, recombinant factor VIII Fc fusion 
protein (rFVIIIFc; Biogen, Cambridge, MA) used to treat hemophilia B, and dulaglutide 
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(TRULICITY®; Eli Lily, Indianapolis, IN) used to treat type 2 diabetes [62]. Engineering the 
biosynthetic pathways for the essential amino acids into HEK cells would increase efficiency and 
lower the costs of HEK293 cell therapeutic production for existing treatments and future proteins 
of interest.  
3.2 Materials and Methods 
3.2.1 Cell Culture and Cell Lines 
 Aseptic cell culture was performed in a biosafety cabinet (Labconco, Kansas City, MO). 
Cells were incubated at 37° C and 5% CO2 in humidified incubators (Thermo Fisher Scientific, 
Carlsbad, CA). HEK293 cells were used for these experiments. They were maintained in 4.5 g/L 
glucose Dulbecco’s modified Eagle’s medium (DMEM) media (Thermo Fisher Scientific, 
Carlsbad, CA).  
3.2.2 Viability Studies 
 HEK cells were plated at 450,000 cells/well in six well tissue culture treated plates 
(Corning, Corning, NY). They were placed under three conditions: 4.5 g/L Dulbecco’s modified 
Eagle’s medium (DMEM) media supplemented with 10% Fetal Bovine Serum; threonine, 
isoleucine, leucine, and valine deprived Dulbecco’s modified Eagle’s medium (DMEM) media 
supplemented with dialyzed Fetal Bovine Serum; and threonine, isoleucine, leucine, and valine 
deprived Dulbecco’s modified Eagle’s medium (DMEM) media supplemented with dialyzed 
Fetal Bovine Serum supplemented with 2.5 mM aspartic acid (Sigma Aldrich). Cell counts were 
taken every 24 hours for six days. One well from each condition was harvested using the media 
from each well to detach the cells from the well of interest. Triplicate live/dead cell counts from 
each of well were performed every day using trypan blue solution (Corning, Corning, NY). Cells 
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were counted on a light microscope (Zeiss, Oberkochen, Germany) using a hemocytometer 
(Electron Microscopy Sciences, Hatfield, PA). 
3.2.3 DNA Constructs and Transfection 
3.2.3.1 Bacterial Genes 
 The genes needed to complete the threonine pathway—thrA, thrB, thrC, and asd—and 
the isoleucine-valine pathway—ILVA, ILVB, ILVC, ILVD, and ILVN—were amplified from E. 
coli by performing polymerase chain reaction (PCR) and inserted into the pFUSE-like vector 
using Gibson assembly. All genes were separated by the porcine teschovirus 2A peptide 
sequence inserted between genes to allow for the use of a single CMV promoter and a 
polycistronic assembly. These two vectors were kindly provided to us by the Silver lab (Figure 
6).   
3.2.3.2 Yeast Genes 
 The genes needed to complete the isoleucine valine-pathway—ILV1, ILV2, ILV3, ILV5, 
and ILV6—were amplified from S. cerevisiae by performing polymerase chain reaction (PCR) 
and individually inserted into the pBudCE4.1 plasmid shown in Figure 7 (Thermo Fisher 
Scientific, Carlsbad, CA) previously.  
3.2.3.3 Transfection 
 Lipofectamine 3000 reagent (Thermo Fisher Scientific, Carlsbad, CA) was used to 
transfect the vectors into HEK293 cells in Opti-MEM I media (Thermo Fisher Scientific, 
Carlsbad, CA) according to the manufacturers protocol.   
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3.2.4 Western Blot 
 Cells were lysed using 1x radioimmunoprecipation assay (RIPA) buffer (Cell Signaling 
Technology; Danvers, MA) containing Complete Mini ethylenediaminetetraacetic acid-free 
protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany). The precipitate was 
separated by centrifugation, and the soluble protein lysate solution was collected. Protein 
concentrations were determined using a BCA protein assay kit (Pierce; Rockford, IL). Samples 
were incubated with 6X SDS loading dye for five minutes at 95°C. Equal amounts of protein 
were loaded into wells of 10% acrylamide gels and separated by electrophoresis for 
approximately two hours at 100 volts. Proteins were transferred to a nitrocellulose membrane 
(Bio-Rad; Hercules, CA) for 75 minutes at 100 volts. Membranes were blocked for two hours in 
TBST solution containing 5% milk. A mouse anti-His tag primary antibody, and an anti-mouse 
HRP-conjugated secondary antibody (Cell Signaling Technology) were used. In addition, a 
mouse anti-V5 tag primary antibody, and an anti-mouse HRP-conjugated secondary antibody 
(Cell Signaling Technology) were also used. Membranes were visualized using a ChemiDoc UV 
transilluminator (Bio-Rad, Hercules, CA) and SuperSignalTM West Pico Chemiluminescent 
Substrate (Thermo Fisher, Carlsbad, CA).   
3.2.5 GC-MS Analysis  
 Intracellular metabolite extraction and GC-MS analysis was performed as previously 







 To determine the impact of essential amino acid depletion on HEK cells, cells were 
cultured on threonine, isoleucine, valine, and leucine depleted media, and normal DMEM media 
(Figure 12). By Day 2 of the study, the HEK cells cultured on essential amino acid limited media 
had a much lower viability than those on normal media that is supplemented with the essential 
amino acids. This trend continues throughout the duration of the six days with the viability of the 
cells on limited media dropping down to below 50% while those on normal DMEM are 






Figure 15: HEK viability under threonine, isoleucine, valine, and leucine 
limited media, and normal media. 
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3.3.2 Western Blots 
 SDS-PAGE was performed on protein lysate from untransfected HEK cells, as well as 
HEK cells transfected with ILV1, ILV2, ILV3, ILV5, and ILV6 individually. Both an anti-His 
and an anti-V5 antibody was used, and the results indicate that each of these genes. ILV1, ILV2, 









Figure 16: Western Blot of ILV1 with anti-V5 antibody. L: ladder; NC: 



















Figure 17: Western Blot of ILV2 with anti-V5 antibody. L: ladder; NC: 
untransfected negative control; ILV2 ≈ 75 kDa 
Figure 18: Western Blot of ILV3 with anti-His antibody. L: ladder; NC: 



















Figure 19: Western Blot of ILV5 with anti-V5 antibody. L: ladder; NC: 
untransfected negative control; ILV5 ≈ 44 kDa 
Figure 20: Western Blot of ILV6 with anti-His antibody. L: ladder; NC: 
untransfected negative control; ILV 6 ≈ 34 kDa 
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3.3.3 GC-MS Analysis 
 Pure samples of 2-oxobutanoate, (S)-3-methyl-2-oxopentanoate, and 2-oxoisovalerate 
(Sigma Aldrich) were individually analyzed through the GC-MS in order to characterize their 
respective profiles for comparison to both HEK cells transfected with ILV1 and untransfected 
HEK cells. Figure 18 indicates the presence of 2-oxobutanoate—or alpha-ketobutyrate—in the 
transfected cells with no peak in the untransfected cells. In addition, it has been thought that the 
final step of valine and isoleucine biosynthesis was present in mammalian cells, but it was 
verified through this analysis as peaks for (S)-3-methyl-2-oxopentanoate (kIle), 2-Oxoisovalerate 
(kVal), and 4-methyl-2-oxopentanoate (kLeu) were detected. 
 
Figure 21: GC-MS analysis of intracellular metabolites in HEK. (A) 
analysis of cells transfected with ILV1 and (B) untransfected negative 
control HEK cells. The arrow shows the presence of 2-oxobutanoate or 




 The viability study demonstrated the reliance of human cells on essential amino acids. 
There was approximately a 30% difference in viability between cells lacking four essential 
amino acids and the cells which were adequately nourished with normal DMEM media. 
Although viability of the amino acid deficient cells drops below 50%, by Day 6, HEK cells can 
be cultured for three days and maintain approximately 65% viability. This could be useful for 
future work involving recreating the entire isoleucine, leucine, and valine biosynthetic pathways 
if an amino acid reduction selection method were to be used. 
The western blots for ILV1, ILV2, ILV3, ILV5, and ILV6 demonstrate that HEK cells 
are capable of expressing their respective genes and producing the enzymes that catalyze the 
steps in the isoleucine and valine biosynthetic pathways. It was made evident that ILV1 was 
expressed in Figure 13 through the band that appears between the 50 kDa and 75 kDa ladder 
bands at approximately 64 kDa—the size of threonine dehydratase. ILV2 expression was proven 
in Figure 14 through the band that appears at nearly 75 kDa which corresponds to the 
approximate size of 75 kDa consistent with acetolactate synthase size. It was also clear that ILV3 
was expressed in Figure 15 through the strong band in between the 50 kDa and 75 kDa ladder 
which is consistent with the size of ketol-acid reductoisomerase which is approximately 63 kDa. 
ILV5 expression (Figure 16) was also proven through the presence of a band right below 50 kDa 
which is consistent with the approximate 44 kDa size of dihydroxy acid dehydratase. Finally, 
ILV6 (Figure 17) expression was proven with the presence of a band right below 37 kDa 




The GC-MS analysis demonstrated that ILV1, threonine dehydratase, took threonine 
from the culture media and catalyzed the conversion of threonine to 2-oxobutanoate. It also 
confirmed that the precursors to isoleucine, valine, and leucine are synthesized within 


















Chapter 4: Overexpression of PGC-1α 
4.1 Introduction 
 As previously mentioned, mammalian cells have become the preferred expression system 
to produce biotherapeutics. There are a number of approaches that can be employed in order to 
increase protein production. The overall goal is to use a metabolic engineering approach by 
overexpressing PCG-1α in order to increase cellular capability through up-regulating 
mitochondrial oxidative metabolism. The benefits of enhancing productivity in a mammalian cell 
line would involve decreased lead times and costs of drug manufacturing. Previous work has 
demonstrated that high-producing Chinese hamster ovary (CHO) cell lines exhibit enhanced 
citric acid cycle activity when compared to its low producing counterparts [43].  
 Increased citric acid cycle activity has been shown to decrease toxic byproduct 
accumulation while also supplying an increased amount of ATP that is crucial to the higher 
energy demands necessary for increased protein production [43]. It is hypothesized that a global 
regulator of mitochondrial metabolism such as PGC-1α may help drive oxidative metabolism 
[27]. PCG-1α overexpression has been shown to increase mitochondrial content, enhance cellular 
respiration, and suppress reactive oxygen species accumulation in a number of different tissues 
[43, 63, 64]. It is beneficial to study the effects of PGC-1α in a prominent industrial cell line such 
as HEK293. The ultimate goal is to identify the metabolic impacts of PGC-1α overexpression 






4.2 Materials and Methods 
4.2.1 Cell Culture and Cell Line 
 Aseptic cell culture was performed in a biosafety cabinet (Labconco, Kansas City, MO). 
Cells were incubated at 37° C and 5% CO2 in humidified incubators (Thermo Fisher Scientific, 
Carlsbad, CA). HEK293 cells were used for these experiments. They were maintained in 4.5 g/L 
glucose Dulbecco’s modified Eagle’s medium (DMEM) media (Thermo Fisher Scientific, 
Carlsbad, CA).  
4.2.2 DNA Constructs and Transfection 
 Plasmids containing PGC-1α were acquired from Addgene. Two plasmids were obtained, 
an untagged PGC-1α plasmid (Figure 19 A)—pSV-PGC1 (Addgene plasmid #3)—and a myc 
tagged PGC1-α plasmid (Figure 19 B)—pcDNA4 myc PGC1-α (Addgene plasmid # 10974). 
Lipofectamine 3000 reagent (Thermo Fisher Scientific, Carlsbad, CA) was used to transfect the 
vectors into HEK293 cells in Opti-MEM I media (Thermo Fisher Scientific, Carlsbad, CA) 
according to the manufacturers protocol.  Stable cell lines were selected for 14 days using 150 





4.2.3 Western Blot 
Cells were lysed using 1x radioimmunoprecipation assay (RIPA) buffer (Cell Signaling 
Technology; Danvers, MA) containing Complete Mini ethylenediaminetetraacetic acid-free 
protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany). The precipitate was 
separated by centrifugation, and the soluble protein lysate solution was collected. Protein 
concentrations were determined using a BCA protein assay kit (Pierce; Rockford, IL). Samples 
were incubated with 6X SDS loading dye for five minutes at 95°C. Equal amounts of protein 
were loaded into wells of 10% acrylamide gels and separated by electrophoresis for 
approximately two hours at 100 volts. Proteins were transferred to a nitrocellulose membrane 
(Bio-Rad; Hercules, CA) for 75 minutes at 100 volts. Membranes were blocked for two hours in 
TBST solution containing 5% milk. A mouse anti-myc tag primary antibody, and an anti-mouse 
HRP-conjugated secondary antibody (Cell Signaling Technology) were used. In addition, a 




rabbit anti-PCG-1α tag primary antibody, and an anti-rabbit HRP-conjugated secondary antibody 
(Cell Signaling Technology) were also used. Membranes were visualized using a ChemiDoc UV 
transilluminator (Bio-Rad, Hercules, CA) and SuperSignalTM West Pico Chemiluminescent 
Substrate (Thermo Fisher, Carlsbad, CA).   
4.2.4 Mitotracker 
 MitoTracker® Red FM (Thermo Fisher, Carlsbad, CA) was used to stain mitochondria 
and assess the effect of PCG1-α overexpression on mitochondria biogenesis. Stable pool 
transfected cells were plated onto 96 well tissue culture treated plates (Corning, Corning, NY) 
and stained according to the manufacturers protocol. Fluorescence was measured at 644 nm 
using the GloMax® multimode plate reader (Promega). Cell counts were also taken in order to 
normalize fluorescence values. One well from each condition was harvested using the media 
from each well to detach the cells from the well of interest. Duplicate live/dead cell counts from 
each of well were performed using trypan blue solution (Corning, Corning, NY). They were 
counted on a light microscope (Zeiss, Oberkochen, Germany) using a hemocytometer (Electron 
Microscopy Sciences, Hatfield, PA). 
4.3 Results 
4.3.1 Western Blots 
 SDS-PAGE was performed on protein lysate from untransfected HEK cells, as well as 
HEK cells transfected with an untagged PGC-1α plasmid, and a Myc-tagged PGC-1α plasmid. 
Both an anti-PGC-1α and an anti-Myc antibody were used. The results indicate that PGC-1α was 







L NC Myc-PGC 
Figure 23: Western Blot of PGC1-α with anti-Myc antibody. L: ladder; NC: 












Figure 24: Western Blot of PGC1-α with anti-PGC1-α antibody. L: ladder; 





 The first attempt at this experiment produced much higher fluorescence values per cell 
for the cells transfected with the Myc PGC-1α plasmid when compared to those transfected with 
a blank plasmid and those not transfected at all (Figure 22). Also, the fluorescence values for the 
cells transfected with the untagged PGC-1α plasmid were slightly less than the negative control 
and blank plasmid transfected HEK cells. This was unexpected as both plasmids had been shown 
to overexpress PGC-1α through transfection.  
 When the mitrotracker protocol was repeated, the transfection was done right into the 96 
well plate which would was stained in order to ensure no loss of cells during transfer to the new 
plate which would be read in the plate reader. Once again, the cells transfected with the Myc 
PGC-1α plasmid exhibited the highest fluorescence (Figure 23); however, the difference was not 
very significant when compared to the other conditions. Once again, the untagged PGC-1α 











































Figure 25: MitoTracker Red Protocol Trial 1 Results 
 





 The Western blots demonstrated that PGC-1α was successfully overexpressed using both 
plasmids. The untagged PGC-1α plasmid resulted in a band consistent with PGC-1α 
overexpression with a much stronger band than the untransfected negative control along with the 
location of the band being consistent with the size of PGC-1α being approximately 105 kDa. In 
addition, the Myc tagged PGC-1α plasmid also resulted in expression as evidenced by the strong 
band around 105 kDa consistent with the correct size. However, upon creation of a stable pool, 
PGC-1α overexpression was not detected through Western blot.  
 The MitroTracker Red protocol suggests that cells overexpressing PGC-1α may be 
creating more mitochondria as evidenced by the higher fluorescence intensity values; however, 
when the experiment was repeated, the differences between the Myc tagged PGC-1α transfection 
and the untransfected negative control and blank plasmid transfection were not as evident. In 
addition, the cells transfected with the untagged PGC-1α plasmid consistently exhibited the 
lowest fluorescence intensities. It should not be concluded that PGC-1α overexpression makes 
more mitochondria through a transient transfection, but perhaps it does over time with a stable 
transfection. There may also be problems with overexpression of PGC-1α through such a simple 







Chapter 5: Conclusion 
 The objective was to work towards engineering a cell line with increased citric acid cycle 
activity without dependence on essential amino acid from culture medium. To do so, PGC-1α 
was overexpressed into HEK cells through a transient transfection and it was determined that 
there may be an increase in mitochondrial biogenesis. Even though generation of a stable pool 
from PGC-1α transfection was achieved, there was no evidence of PGC-1α overexpression 
through Western blot.  
In addition, a synthetic biology approach was taken in order to begin constructing the 
biosynthetic pathway for isoleucine and valine through the expression of ILV1, ILV2, ILV3, 
ILV5, and ILV6. In addition, ILV1 activity was verified through GC-MS analysis and the first 
metabolite in the isoleucine-valine pathway, oxobutanoate, was produced upon transient 
transfection in HEK cells. In addition, the presence of amino-acid transaminase in mammalian 
cells was confirmed through the presence of isoleucine, valine, and leucine precursors (kIle, 
kVal, and kLeu respectively).  
Furthermore, viability studies were performed to further verify the expression of the 
threonine biosynthetic pathway in a U-2 OS cell line. It was found that normal U-2 OS cells 
could not withstand the extended absence of threonine. More viability studies were performed in 
HEK cells to determine sustainability in the absence of four essential amino acids—threonine, 
isoleucine, leucine, and valine. HEK cells demonstrated a large decrease in viability while 
lacking these amino acids, but they appeared to not be as adversely affected as U-2 OS cells 
when lacking essential amino acids. This could prove to be useful if essential amino acid 
depletion is used as the selection method for construction of the isoleucine, valine, threonine, and 
leucine pathways into an HEK cell line due to their robustness. 
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Chapter 6: Future Work 
6.1 Completion of Isoleucine/Valine pathway in HEK cells 
Further work should focus on advancing the biosynthetic pathway of isoleucine and 
valine past oxobutanoate and proving metabolite formation. In addition, it may be valuable to 
repeat the creation of a threonine prototrophic cell line but in HEK, cells because they are more 
industrially relevant for the biopharmaceutical industry and were shown to be more robust when 
cultured with amino acid limited media. 
6.2 Metabolic Flux Analysis in U-2 OS Threonine Prototrophic Cell Line 
 Elucidating the entire threonine biosynthetic pathway through 13Carbon labeling in the U-
2 OS prototrophic cell line would give a novel view of the pathway into a human cell line. It 
would help guide further efforts to create a cell line capable of producing its own essential amino 
acids by knowing which amino acids are secreted and consumed the most. Furthermore, other 
selection methods could be explored in order to find higher threonine producing clones.  
6.3 Stable Pool of HEK Cells Overexpressing PGC-1α 
The next step would be to produce a stable pool of HEK cells overexpressing PGC-1α 
and verifying through Western blot. Furthermore, the use of the MitoTracker protocol could 
show a significant increase in the mitochondrial content of cells overexpressing PGC-1α. Upon 
completion of a stable pool that is shown to increase mitochondrial biogenesis, high producing 
clones can be selected along with performing a metabolic assay to observe the differences in 
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